Role of the 5-HT 1A serotonergic system in anxiolytic-like effects of silymarin

Neurophysiology

Volumn 44, Issue 1, 2012, Pages 49-55

  Solati, J ^a   Yaghmaei, P ^b   Mohammdadi, K ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

5 HT 1A receptors; anxiety; herbal medicine; rat; serotonergic system; silymarin

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; SEROTONIN 1A RECEPTOR; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; MALE; MAZE TEST; NEUROMODULATION; NONHUMAN; OPEN ARM ENTRY; OPEN ARM TIME; PHARMACOLOGICAL PARAMETERS; RAT; SEROTONINERGIC SYSTEM; STEREOTAXIC SURGERY; THERAPY EFFECT; TRANQUILIZING ACTIVITY;

EID: 84859766804     PISSN: 00902977     EISSN: 15739007     Source Type: Journal    
DOI: 10.1007/s11062-012-9266-0     Document Type: Article

References (32)

1. R. Krueger, "The structure of common mental disorders,"Arch. Gen. Psychiat., 56, No. 10, 921-926 (1999).
2. H. Wittchen and J. Hoyer, "Generalized anxiety disorder: nature and course," J. Clin. Psychiat., 62, Suppl. 11, 15-21 (2001).
3. R. Kessler, J. Soukup, R. Davis, et al., "The use of complementary and alternative therapies to treat anxiety and depression in the United States," Am. J. Psychiat., 158, 289-294 (2001).
4. D. Eisenberg, R. Davis, S. Ettner, et al., "Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey," Jama, 280, No. 18, 1569-1575 (1998).
5. J. Astin, "Why patients use alternative medicine: results of a national study," Jama, 279, No. 19, 1548-1553 (1998).
6. L. Seeff, K. Lindsay, B. Bacon, et al., "Complementary andalternative medicine in chronic liver disease," Hepatology, 34, No. 3, 595-603 (2001).
7. S. Verma and P. Thuluvath, "Complementary and alternative medicine in hepatology: review of the evidence of efficacy," Clin. Gastroenterol. Hepatol., 5, No. 4, 408-416 (2007).
8. T. Listings, From Wikipedia (View original Wikipedia Article). Last modified on 29 July, 2010, at 17: 49.
9. P. Lu, T. Mamiya, L. Lu, et al., "Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment," Behav. Brain Res., 207, No. 2, 387-393 (2009).
10. R. Lanzenberger, M. Mitterhauser, C. Spindelegger, et al., "Reduced serotonin-1A receptor binding in social anxiety disorder," Biol. Psychiat., 61, No. 9, 1081-1089 (2007).
11. 1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action?" Prog. NeuroPsychopharmacol. Biol. Psychiat., 17, No. 1, 87-104 (1993).
12. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego (2007).
13. R. J. Rodgers and N. J. Johnson, "Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety," Pharmacol. Biochem. Behav., 52, No. 2, 297-303 (1995).
14. M. R. Zarrindast, J. Solati, S. Oryan, et al., "Effect of intra-amygdala injection of nicotine and GABA receptor agents on anxiety-like behaviour in rats," Pharmacology, 82, No. 4, 276-284 (2008).
15. K. Thomas and P. Coleman, "Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey," J. Public Health, 26, No. 2, 152-157 (2004).
16. C. Lengacher, M. Bennett, K. Kip, et al., "Frequency of use of complementary and alternative medicine in women with breast cancer," Oncology Nursing Forum, 29, No. 10, 1-9 (2002).
17. G. van der Watt, J. Laugharne, and A. Janca, "Complementary and alternative medicine in the treatment of anxiety and depression," Curr. Opin. Psychiat., 21, No. 1, 37-42 (2008).
18. P. Barnes, E. Powell-Griner, K. McFann, et al., "Complementary and alternative medicine use among adults: United States, 2002," Adv. Data, 27, 54-71 (2004).
19. E. Mazzio, N. Harris, and K. Soliman, "Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells," Planta Med., 64, No. 7, 603-606 (1998).
20. M. Osuchowski, V. Johnson, Q. He, et al., "Alterations in regional brain neurotransmitters by silymarin, a natural antioxidant flavonoid mixture, in BALB/c mice,"Pharmaceutical Biol., 42, Nos. 4/5, 384-389 (2004).
21. E. Akimova, R. Lanzenberger, and S. Kasper, "The serotonin-1A receptor in anxiety disorders," Biol. Psychiat., 66, No. 7, 627-635 (2009).
22. H. Goldberg and R. Finnerty, "The comparative efficacy of buspirone and diazepam in the treatment of anxiety," Am. J. Psychiat., 136, 1184-1187 (1979).
23. R. Gammans, J. Stringfellow, A. Hvizdos, et al., "Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms," Neuropsychobiology, 25, No. 4, 193-201 (1992).
24. 1A antagonists," Trends Neurosci., 19, No. 9, 378-383 (1996).
25. 1Areceptor mutant mice," Proc. Natl. Acad. Sci. USA, 95, 15049-15054 (1998).
26. 1A receptor antagonist NAN190 injected into rat CA1 hippocampal area," Gen. Pharmacol., 28, No. 3, 435-441 (1997).
27. 1A receptor modulation of anxiety in two ethological animal tests," J. Neurosci., 16, No. 15, 4810-4815 (1996).
28. 1Apresynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action," Eur. J. Pharmacol., 138, No. 1, 53-60 (1987).
29. 1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?" J. Pharmacol. Exp. Ther., 272, No. 2, 920-929 (1995).
30. P. Chua, M. Krams, I. Toni, et al., "A functional anatomy of anticipatory anxiety," NeuroImage, 9, 563-571 (1999).
31. J. Kazer and A. Sharkey, "The septo-hippocampal system and anxiety: A robot simulation," in: ICANN99 Ninth International Conference on Artificial Neural Networks (7-10 September, 1999), Vol. 1, Univ. of Edinburg, UK (1999), pp. 389-394.
32. M. Davis, "The role of the amygdala in fear and anxiety,"Ann. Rev. Neurosci., 15, 353-375 (1992).